Chemical structure of molecule Aficamten

oral QD myosin inhibitor (IC50 = 1.4 µM)

Ph. II candidate for cardiomyopathy (5-30 mg)

from HTS w/ bovine cardiac muscle myofibrils

Journal of Medicinal Chemistry

Cytokinetics, South San Francisco, CA

The Cytokinetics next-generation myosin inhibitor, aficamten, is a phase II candidate for genetic hypertrophic cardiomyopathies, and is orally dosed between 5-30 mg QD. It follows BMS’s mavacamten (acquired from Myokardia in…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.